

University of Massachusetts Medical School

eScholarship@UMMS

---

UMass Center for Clinical and Translational  
Science Research Retreat

2014 UMass Center for Clinical and  
Translational Science Research Retreat

---

May 20th, 12:30 PM

## Isolation of Human Antigen-Specific Antibodies from Memory B-Cells Nearly Two Years Post Vaccination


Stuart Nelson

*University of Massachusetts Medical School*

*Et al.*

Let us know how access to this document benefits you.

Follow this and additional works at: [https://escholarship.umassmed.edu/cts\\_retreat](https://escholarship.umassmed.edu/cts_retreat)

 Part of the [Immunoprophylaxis and Therapy Commons](#), [Medicinal Chemistry and Pharmaceutics Commons](#), [Therapeutics Commons](#), and the [Translational Medical Research Commons](#)

---

Nelson S, Crowley A, Thomas WD, Souders CA. (2014). Isolation of Human Antigen-Specific Antibodies from Memory B-Cells Nearly Two Years Post Vaccination. UMass Center for Clinical and Translational Science Research Retreat. Retrieved from [https://escholarship.umassmed.edu/cts\\_retreat/2014/posters/84](https://escholarship.umassmed.edu/cts_retreat/2014/posters/84)

Creative Commons License



This work is licensed under a [Creative Commons Attribution-NonCommercial-Share Alike 3.0 License](#).

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For more information, please contact [Lisa.Palmer@umassmed.edu](mailto:Lisa.Palmer@umassmed.edu).

## **Isolation of Human Antigen-Specific Antibodies from Memory B-Cells Nearly Two Years Post Vaccination**

Stuart Nelson<sup>1</sup>, Andrew Crowley<sup>1</sup>, William Thomas<sup>1</sup> and Colby A Souders<sup>1</sup>

MassBiologics of the University of Massachusetts Medical School, Department of Product Discovery<sup>1</sup>, 460 Walk Hill St, Boston, MA 02126.

Corresponding Author: Colby.Souders@umassmed.edu, (617)-474-4050

### **Abstract:**

Isolation and production of therapeutic human monoclonal antibodies (mAbs) traditionally utilizes a handful of techniques including antibody engineering, phage display, hybridoma generation from transgenic mice or EBV immortalization of B-cells. Over the past decade a new approach has emerged that attempts to extract antigen-specific memory B-cells from the peripheral blood of individuals vaccinated or infected with the target. Initial attempts focused on culturing B-cells and inducing differentiation to plasmablasts for analysis of antibody-antigen specificity, but results were largely mixed due to difficult culture conditions and/or rarity of target cells. With advancing technology in cell sorting, single antigen-specific memory B-cells can be identified and sorted with fluorescently labeled antigens. This method has produced virus-specific mAbs from HIV-infected patients and tetanus-specific mAbs within weeks after Tdap immunization. Many other studies claim to have found antigen-specific mAbs months to years after immunization or clearance of an infection; however, these studies fail to provide direct evidence of antibody specificity by cloning and expressing the mAbs from B-cells.

Here we report the efficient isolation of tetanus-specific mAbs from a subject Td-immunized almost two years prior to blood draw. Initially, the total B-cell population was isolated from peripheral blood mononuclear cells enriched by negative selection, then stained to identify tetanus-specific memory B-cells. These cells were individually sorted and PCR was performed to amplify heavy and light chain variable regions of the B-cell's antibody mRNA. After sequencing, 15 of 42 samples produced both heavy and light chain antibody sequence and 11 mAbs were cloned and transiently expressed. ELISA analysis indicated 5 of the 11 mAbs bound the Hc protein fragment of tetanus toxin and 3 were specific for Hc. We plan to extend this initial success to additional targets and longer gaps between vaccination and B-cell isolation to identify functional therapeutic human antibodies.